Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma

Human Gene Therapy

Volumn 23, Issue 1, 2012, Pages 98-103

  Zhang, Yadong ^a   Duan, Dongsheng ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; NEURONAL NITRIC OXIDE SYNTHASE; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; MALE; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SARCOLEMMA; VIRAL GENE THERAPY;

ANIMALS; BLOTTING, WESTERN; DEPENDOVIRUS; DYSTROPHIN; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; NITRIC OXIDE SYNTHASE TYPE I; PLASMIDS; SARCOLEMMA;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 84862908306     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.131     Document Type: Article

References (31)

1. Beggs, A.H., Hoffman, E.P., Snyder, J.R., et al. (1991). Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am. J. Hum. Genet. 49, 54-67. (Pubitemid 21891653)
2. Brenman, J.E., Chao, D.S., Xia, H., et al. (1995). Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82, 743-752.
3. Clemens, P.R., Krause, T.L., Chan, S., et al. (1995). Recombinant truncated dystrophin minigenes: construction, expression, and adenoviral delivery. Hum. Gene Ther. 6, 1477-1485.
4. Duan, D. (2006). From the smallest virus to the biggest gene: marching towards gene therapy for Duchenne muscular dystrophy. Discov. Med. 6, 103-108.
5. Duan, D. (2011). Duchenne muscular dystrophy gene therapy: lost in translation? Res. Rep. Biol. 2, 31-42.
6. Duan, D., Yue, Y., and Engelhardt, J.F. (2001). Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther. 4, 383-391. (Pubitemid 33040525)
7. Duan, D., Yan, Z., and Engelhardt, J.F. (2006). Expanding the capacity of AAV vectors. In Parvoviruses. M.E. Bloom, S.F. Cotmore, R.M. Linden, C.R. Parrish, and J.R. Kerr, eds. (Hodder Arnold; distributed in the United States by Oxford University Press, London, New York) pp. 525-532.
8. England, S.B., Nicholson, L.V., Johnson, M.A., et al. (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180-182.
9. Flanigan, K.M., Dunn, D.M., Von Niederhausern, A., et al. (2009). Mutational spectrum of DMD mutations in dystro-phinopathy patients: application of modern diagnostic techniques to a large cohort. Hum. Mutat. 30, 1657-1666.
10. Ghosh, A., and Duan, D. (2007). Expending adeno-associated viral vector capacity: a tale of two vectors. Biotechnol. Genet. Eng. Rev. 24, 165-177. (Pubitemid 350032948)
11. Ghosh, A., Yue, Y., and Duan, D. (2006). Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J. Gene Med. 8, 298-305.
12. Ghosh, A., Yue, Y., Lai, Y., and Duan, D. (2008). A hybrid vector system expands aden-associated viral vector packaging capacity in a transgene independent manner. Mol. Ther. 16, 124-130.
13. Ghosh, A., Yue, Y., and Duan, D. (2011). Efficient transgene re-constitution with hybrid dual AAV vectors carrying the minimized bridging sequence. Hum. Gene Ther. 22, 77-83.
14. Gillard, E.F., Chamberlain, J.S., Murphy, E.G., et al. (1989). Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene. Am. J. Hum. Genet. 45, 507-520. (Pubitemid 19261438)
15. Grange, R.W., Isotani, E., Lau, K.S., et al. (2001). Nitric oxide contributes to vascular smooth muscle relaxation in contracting fast-twitch muscles. Physiol. Genomics 5, 35-44. (Pubitemid 33675200)
16. Harper, S.Q., Hauser, M.A., Dellorusso, C., et al. (2002). Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253-261. (Pubitemid 34250103)
17. Koenig, M., Beggs, A.H., Moyer, M., et al. (1989). The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet. 45, 498-506. (Pubitemid 19261437)
18. Kunkel, L.M. (2005). 2004 William Allan Award address. Cloning of the DMD gene. Am. J. Hum Genet. 76, 205-214.
19. Lai, Y., Yue, Y., Liu, M., et al. (2005). Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol. 23, 1435-1439. (Pubitemid 41679397)
20. Lai, Y., Thomas, G.D., Yue, Y., et al. (2009). Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarco-lemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest. 119, 624-635.
21. Lai, Y., Yue, Y., and Duan, D. (2010). Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome 〉 or = 8.2 kb. Mol. Ther. 18, 75-79.
22. Li, D., Bareja, A., Judge, L., et al. (2010). Sarcolemmal nnos anchoring reveals a qualitative difference between dystrophin and utrophin. J. Cell Sci. 123, 2008-2013.
23. Li, D., Yue, Y., Lai, Y., et al. (2011). Nitrosative stress elicited by nNOS micro delocalization inhibits muscle force in dystro-phin-null mice. J. Pathol. 223, 88-98.
24. Li, S., Kimura, E., Ng, R., et al. (2006). A highly functional mini-dystrophin/Gfp fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum. Mol. Genet. 15, 1610-1622. (Pubitemid 43904827)
25. Lostal, W., Bartoli, M., Bourg, N., et al. (2010). Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum. Mol. Genet. 19, 1897-1907.
26. Odom, G.L., Gregorevic, P., Allen, J.M., and Chamberlain, J.S. (2011). Gene therapy of mdx mice with large truncated dys-trophins generated by recombination using rAAV6. Mol. Ther. 19, 36-45.
27. Qiao, C., Zhang, W., Yuan, Z., et al. (2010). AAV6 capsid tyrosine to phenylalanine mutations improve gene transfer to skeletal muscle. Hum. Gene Ther. 21, 1343-1348.
28. Rodino-Klapac, L.R., Montgomery, C.L., Bremer, W.G., et al. (2010). Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol. Ther. 18, 109-117.
29. Thomas, G.D., Sander, M., Lau, K.S., et al. (1998). Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc. Natl. Acad. Sci. U. S. A. 95, 15090-15095. (Pubitemid 29003761)
30. Yue, Y., Li, Z., Harper, S.Q., et al. (2003). Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 108, 1626-1632. (Pubitemid 37187791)
31. Zhong, L., Li, B., Mah, C.S., et al. (2008). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U. S. A. 105, 7827-7832. (Pubitemid 351872723)